Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to learn more about whether the combination of drugs
carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC). One of the
standard treatments for advanced NSCLC is the combination of the drugs carboplatin,
paclitaxel and Avastin. Paclitaxel can be associated with severe side effects that may make
the treatment difficult to tolerate. Some of these side effects are caused by the solution
used to dissolve paclitaxel before it can be administered. Abraxane is a different form of
paclitaxel that does not need to be dissolved by this solution. Abraxane is approved for the
treatment of breast cancer but is not approved to treat NSCLC. We will also be trying to
learn more about how the drug Avastin may work to treat cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Celgene Corporation Dana-Farber Cancer Institute Genentech, Inc.